Malignancy in MRTs is driven by massive changes in the epigenome due to SMARCB1 loss accompanied by changes in the expression of hundreds of genes leading to an undifferentiated tumour phenotype with a very poor prognosis. Here, SMARCB1 is linked to neoplasm.